(Amended) A method of treating undesired angiogenesis in a human or animal comprising the step of administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of an angiogenesis-inhibiting compound selected from the group consisting of 3-aminothalidomide, and 3-hydroxythalidomide, and metabolites or hydrolysis products of 3-aminothalidomide and metabolites or hydrolysis products of 3-hydroxythalidomide, and mixtures thereof.

[the following compounds:

$$R_{2}$$

$$R_{3}$$

$$R_{4}$$


$$R_{6}$$

$$R_{8}-R_{9}$$

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> can be selected from: -H; -OH; =O, straight chained and branched alkanes, alkenes, alkenes, eyclic alkanes, alkenes, and alkynes; combinations of cyclic and acyclic alkanes, alkenes, and alkynes; alcohol, aldehyde, ketone, carboxylic acid, ester, or ether moieties in combination with acyclic, cyclic, or combination acyclic/cyclic moieties; aza; amino; -XO<sub>n</sub> or -O-XO<sub>n</sub>, (where X=N and n=2; X=S and n=2 or 3; or X=P and n=1-3); and halogens; R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, and R<sub>8</sub> are each independently selected from:

$$Y Y = Y - C - R_{10}; -N - R_{10};$$

or -O- where Y is optional and is the same as defined above for  $R_1$ ; and  $R_{10}$  is the same as defined above for  $R_1$ , or (where Y is absent)  $R_{10}$  is =O; and  $R_9$  is a moiety having formula A) or B):



where each of R<sub>11</sub> - R<sub>17</sub> is independently the same as defined above for R<sub>5</sub>;

B)
$$R_{18}$$
 $-C-R_{19}$ 
 $R_{20}$ 

where R<sub>18</sub>, R<sub>19</sub> and R<sub>20</sub> are, independently selected from

and n=1 to 4.]

Please add the following claims:

41. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in retinopathy of prematurity.

42. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in corneal graft rejection.

43. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in neovascular glaucoma.

4. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in retrolental fibroplasia.

45. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in epidemic keratoconjunctivitis.

46. (New) The method of Claim 25 wherein the undesired angiogenesis occurs due to Vitamin A deficiency.

47. (New) The method of Claim 25 wherein the undesired angiogenesis occurs due to contact lens overwear.

48. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in atopic keratitis.

49. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in superior limbic keratitis.

50. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in pterygium keratitis sicca.

51. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in sogrens.

52. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in acne rosacea.

53. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in phylectenulosis.

54. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in syphilis.

5\hat{\chi}. (New) The method of Claim 2\hat{\chi} wherein the undesired angiogenesis occurs in Mycobacteria infections other than leprosy.

56. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in lipid degeneration.

57. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in chemical burns.

58. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in bacterial ulcers.

5Q. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in fungal ulcers.

(New) The method of Claim 25 wherein the undesired angiogenesis occurs in Herpes simplex infections.

61. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in Herpes zoster infections.

(New) The method of Claim 25 wherein the undesired angiogenesis occurs in protozoan infections.

63. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in Kaposi's sarcoma.

30 64. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in Mooren ulcer.

65. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in Terrien's marginal degeneration.

08/468,792 The method of Claim 25 wherein the undesired angiogenesis occurs in The method of Claim 25 wherein the undesired angiogenesis is caused by 8√7. (New) trauma. The method of Claim 25 wherein the undesired angiogenesis occurs in 68. (New) rheumatoid arthritis. 69. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in systemic lupus. The method of Claim 25 wherein the undesired angiogenesis occurs in (New) polyarteritis. The method of Claim 25 wherein the undesired angiogenesis occurs in (New) Wegeners sarcoidosis. The method of Claim 25 wherein the undesired angiogenesis occurs in **%**. (New) scleritis The method of Claim 2/5 wherein the undesired angiogenesis occurs in 78. (New) Steven's Johnson disease. The method of Claim 2/5 wherein the undesired angiogenesis occurs in eriphigoid radial keratotomy. The method of Claim 28 wherein the undesired angiogenesis occurs in sickle cell anemia. The method of Claim 25 wherein the undesired angiogenesis occurs in (New) sarcoid The method of Claim 2/5 wherein the undesired angiogenesis occurs in  $\mathcal{N}$ . (New) pseudoxanthoma elasticum. The method of Claim 25 wherein the undesired angiogenesis occurs in Pagets disease. The method of Claim 25 wherein the undesired angiogenesis occurs in 79. (New) vein occlusion. The method of Claim 25 wherein the undesired angiogenesis occurs in artery occulsion. The method of Claim 2/5 wherein the undesired angiogenesis occurs in carotid obstructive disease. The method of Claim 25 wherein the undesired angiogenesis occurs in 82. (New) chronic uveitis. The method of Claim 2/5 wherein the undesired angiogenesis occurs in

83. (New)

chronic vitritis.

08/468,792 Page 6 The method of Claim 25 wherein the undesired angiogenesis occurs in (New) Lyme's disease. \$5. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in Eales disease. The method of Claim 25 wherein the undesired angiogenesis occurs in Bechets disease. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in myopia. The method of Claim 25 wherein the undesired angiogenesis occurs in (New) optic pits. New) The method of Claim 25 wherein the undesired angiogenesis occurs in Stargarts disease. The method of Claim 25 wherein the undesired angiogenesis occurs in pars planitis. The method of Claim 25 wherein the undesired angiogenesis occurs in chronic retinal detachment. The method of Claim 25 wherein the undesired angiogenesis occurs in 92. (New) hyperviscosity syndromes. The method of Claim 25 wherein the undesired angiogenesis occurs in 93. (New) toxoplasmosis. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in post-laser complications. 95. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in abnormal proliferation of fibrovascular tissue. 96. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in hemangiomas. 63 The method of Claim 25 wherein the undesired angiogenesis occurs in 97. (New) Osler-Weber-Rendu. 98. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in solid tumors.

90. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in blood borne tumors.

100. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in acquired immune deficiency syndrome.

101. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in ocular neovascular disease.

08/468,792 Page 7

102. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in osteoarthritis.

103. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in diseases caused by chronic inflammation.

104. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in Crohn's disease.

105. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in ulceritive colitis.

106. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in the tumors of rhabdomyosarcoma.

107. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in the tumors of retinoblastoma.

108. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in the tumors of Ewing sarcoma.

109. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in the tumors of neuroblastoma.

10. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in the tumors of osteosarcoma.

1 (New) The method of Claim 25 wherein the undesired angiogenesis occurs in leukemia.

112. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in psoriasis.

113. (New) The method of Claim 25 wherein the undesired angiogenesis occurs in atherosclerosis.

**REMARKS** 

The present invention is directed to methods of treating undesired angiogenesis. Applicant has amended Claim 25 and added new Claims 41-113. Claims 25, and 35-113 are pending in this application. Claims 26-34 have been canceled. Support for the newly added claims is found in Applicant's specification at pages 2-6.

Sull.